Thyroid pharma
-
2014 ATA thyroid therapy guidelines: 1. Levothyroxine
In this series of posts, I paraphrase a 2014 thyroid therapy guidelines document in a way that even the brain-fogged hypothyroid patient can understand more quickly and easily than reading the original version. Posts in this series: 2014 ATA Thyroid therapy guidelines: 1. Levothyroxine [this post] 2014 ATA Thyroid therapy guidelines: 2. Ethics 2014 ATA…
-
Pharma prejudice refuses a paradigm shift in thyroid therapy
This post engages in a moral argument, not a scientific one. Thyroid pharmaceutical prejudice is part of a paradigm that is refusing to shift. We need to keep asking key questions and fight together for this shift. Look around you today. Thyroid guidelines and health care systems currently treat all thyroid patients as one undifferentiated…
-
Thyroid pharma: Bioidentical yet harmful?
Any fair criticism of a medication’s potential for harm or benefit should first examine the properties of the medication and how it interacts with the human body in general. Next, we should distinguish the content of a pharmaceutical tool from its use (dosing adjustments, circumstances). Then finally, we should consider this: The therapy has to…
-
Pharmaceutical prejudice can lead to a thyroid therapy dystopia
I really DON’T want to be gloomy all the time. I DO believe there is hope for positive change in thyroid therapy today. But now and then we have to consider “what is the worst that could happen?” I want to show you where we are now, where we could all be headed if we…
-
Thyroid pharmaceutical prejudice: How it works
By Tania S. Smith. Updated May 8, 2019 “Thyroid pharmaceutical prejudice” is simply a bias against one thyroid hormone pharmaceutical type in favor of another. Prejudice claims that a particular thyroid medication is intrinsically unsafe or ineffective, for all patients under almost all circumstances. It’s a type of “sweeping generalization” fallacy. The main aim of…